ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0314

PROMIS Provides a Broad Overview of Health-Related Quality of Life in the Evaluation of Sjogren’s Syndrome

Dana DiRenzo1, Susan Robinson2, Clifton Bingham1, Alan Baer3 and Thomas Grader-Beck1, 1Johns Hopkins University, Baltimore, MD, 2Johns Hopkins, Baltimore, MD, 3Johns Hopkins University School of Medicine, Baltimore, MD

Meeting: ACR Convergence 2021

Keywords: Patient reported outcomes, quality of life, Sjögren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 6, 2021

Title: Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: Sjogren’s Syndrome (SS) is a systemic autoimmune disease that has considerable impact on health-related quality of life (HRQL). The European League Against Rheumatism (EULAR) Sjogren’s Syndrome Patient Reported Index (ESSPRI) is the most widely used questionnaire to evaluate severity of patient-reported symptoms but is limited in scope. We sought to evaluate predictors of pain, fatigue, and social participation in SS using the Patient Reported Outcome Measurement Information System (PROMIS®) HRQL instruments to supplement ESSPRI findings.

Methods: A cross-sectional evaluation was performed on completed questionnaires of consecutive adult patients during visits to a multidisciplinary Sjogren’s clinic between March 2018-February 2020. Questionnaires included PROMIS short-forms (depression 4a.v1, anxiety 4a.v1, fatigue 8a.v1, physical function 4a.v2, pain interference 8a.v1 (PI), sleep disturbance 4a.v1, participation in social roles and activities 8a.v1) and the ESSPRI. Patients were either classified as SS by 2016 ACR/EULAR criteria or labeled as “sicca not otherwise specified” (NOS) and used as a comparison group. Descriptive statistics were calculated for disease-related and sociodemographic variables and Pearson correlation was used to evaluate the relationship between subdomains of the ESSPRI and PROMIS. Uni- and multivariable linear regression (MVR) models were used to evaluate predictors of PROMIS PI, fatigue, and social participation after controlling for age, gender, race, ethnicity, and symptom duration.

Results: 227 SS patients and 85 patients with sicca NOS were included. Patients with SS were slightly older (mean (SD) years 57 (14) vs 54 (12), p=0.030) and were mostly female and white (Table 1). Mean (SD) PROMIS T-scores for PI (56.9 (11.0)), fatigue (57.2 (10.6)), and physical function (44.2 (9.8)) were at least ½ SD worse than US population normative values. Among SS patients PROMIS PI (r=0.72) and fatigue (r=0.80) highly correlated with respective ESSPRI pain and fatigue sub-domains. PI, sleep disturbance, poor physical function, and impaired social participation predicted fatigue and similarly fatigue, sleep disturbance, poor physical function, and impaired social participation predicted PI (all p’s< 0.01) (Table 2). Fatigue and PI, but not dryness or mood disturbance, were the strongest predictors of social participation in MVR in this SS cohort. Patients with sicca NOS had greater mean T-Scores (SD) for PI (60.3 (12.0)) than the SS cohort in addition to worse social participation (43.5 (11.7)) and SD (55.4 (10.6)) (p’s < 0.05). There were no significant differences in ESSPRI domains between patients with SS and sicca NOS.

Conclusion: In our SS cohort, PROMIS PI and fatigue scores correlated highly with respective ESSPRI domains. Fatigue and PI, but not dryness, were found to be the strongest negative predictors of social participation. Given the ability of PROMIS instruments to identify HRQL domains of high impact on SS patients beyond those ascertained through ESSPRI, these questionnaires should be considered as a supplement when evaluating SS patients in clinical care and trials.

Table 1. Baseline demographic and clinical characteristics of patients who met 2016 ACR/EULAR Classification Criteria for Sjogren’s Syndrome compared to those with sicca not otherwise specified (NOS).

Table 2. Predictors of fatigue, pain, and Social Participation after controlling for age, gender, race, ethnicity, and symptom duration. *Standardized Beta reported.


Disclosures: D. DiRenzo, None; S. Robinson, None; C. Bingham, Bristol Myers Squibb, 5, Abbvie, 2, Gilead, 2, Eli Lilly, 2, Janssen, 2, Regeneron, 2, Pfizer, 2, Sanofi, 2; A. Baer, Bristol Myers Squibb, 2, UpToDate, 9; T. Grader-Beck, Novartis, 2, Abbvie, 5, Eli Lilly, 2, Celgene, 5.

To cite this abstract in AMA style:

DiRenzo D, Robinson S, Bingham C, Baer A, Grader-Beck T. PROMIS Provides a Broad Overview of Health-Related Quality of Life in the Evaluation of Sjogren’s Syndrome [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/promis-provides-a-broad-overview-of-health-related-quality-of-life-in-the-evaluation-of-sjogrens-syndrome/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/promis-provides-a-broad-overview-of-health-related-quality-of-life-in-the-evaluation-of-sjogrens-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology